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ABSTRACT
Objective: The aim of this study is to provide comprehensive information of oncolytic viral therapy, from the origin to present scenario.
Methods: This observational study was conducted by the Department of Pharmacology, Saveetha Medical College, Chennai between July and December 
2016. Date regarding ongoing oncolytic virotherapy trials was retrieved from clinical trial database, United States and Clinical trial registry forum, 
India. Tamilnogene approval details were obtained from the US-Food and Drug Administration approval new drug approval information.
Results: Eleven ongoing trials in Phase I and Ia are being carried out, of which 4 viral strains such as herpes, adenovirus, measles, and reovirus are 
used for intracerebral malignancies. Four trials have shown superior effects and seven trial results are yet to be completed.
Conclusion: Oncolytic viral therapy can be as effective as targeted therapy in battling against cancer; however, long-term efficacy and safety should 
be established from more studies and meta-analysis.
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INTRODUCTION
Oncolytic viral therapy is yet another milestone in targeted 
chemotherapy; however, the ground work has started as early as in 
1950s to use viruses to shut off cancer cell cycle [1]. Despite several 
hurdles, now, we are able to get a nod for the first oncolytic viral therapy 
for advanced cases of skin cancer, melanoma.
The tryst with virotherapy began in 1949, when by chance, 2 patients 
with Hodgkin’s Lymphoma went into remission. However, the happy 
times came with a price of dealing with another entity, namely, 
hepatitis B [2]. Like many famous discoveries, this was one of chance. 
Later, a trial was conducted with 22 patients wherein they were 
administered strains of hepatitis B virus [3]. Of the 22 patients, 
4 showed mild forms of recovery. There was one death reported in 
this trial.
Moreover, then 7 years later, another study was conducted, this 
time with a significant idea of what we needed and how it probably 
worked. As mentioned earlier, this study was done with the adenovirus 
adenoidal, pharyngeal, and conjunctival. The disease against which it 
was administered was advanced epidermoid cervical carcinoma. There 
were 30 patients in the trial. The trial was mildly promising mostly 
because the patients were still alive post inoculation [4]; however, the 
most significant strain of adenovirus came with the finding and usage 
of H101 strain. It was approved in 2005 by the Chinese SFDA. However, 
it is not approved outside of China. It is marketed under the name 
ONCORINE.
METHODS
This observational study was conducted by the Department of 
Pharmacology, Saveetha Medical College, Chennai between July and 
December 2016. Date regarding ongoing oncolytic virotherapy trials 
was retrieved from clinical trial database, United States and Clinical 
trial registry forum, India. Talimogene approval details were obtained 
from the US-Food and Drug Administration approval new drug approval 
information.
RESULTS
Eleven ongoing trials in Phase I and Ia are being carried out, of which 
4 viral strain such as herpes, adenovirus, measles, and reovirus are 
used for intracerebral malignancies. Four trials have shown superior 
effects and seven trial results are yet to be completed.
DISCUSSION
How does virotherapy works?
There are 4 proposed mechanisms of action, each one being strongly 
expressed in a particular strain and varies with each other [5]. The 
postulated mechanisms are:
•	 Cell	 lysis	by	 replication	 in	 the	cell:	The	 first	possible	action	and	
probably	the	most	significant
•	 In vivo synthesis of proteins and cytotoxic products that is 
detrimental to the cell
•	 Induction	 of	 antitumour	 responses,	 both	 direct	 and	 immune	
mediated
•	 Transgene	expression	and	induction	cancer	cell	apoptosis.
Mechanism is illustrated is depicted in Fig. 1.
Current cancer chemotherapy scenario with oncolytic viruses
Primary brain tumors are extensively studied under oncolytic therapy 
in experimental model as well as in clinical trials. Central Nervous 
system tumors originate from a common progenitor which then 
differentiates into one of the glial cell types. They generally include 
astrocytomas, oligodendroglioma, and ependymoma. Glioblastoma 
multiforme (Grade IV astrocytoma) belongs to a set of tumors called 
infiltrating astrocytomas.
Genetically engineered herpes simplex virus-dlsptk by Martuza and 
colleagues, it is lacking the viral thymidine kinase. This component is 
important for replication in nonreplicating cells. Its deletion thus made 
it incompetent to divide into cells like neurons and infects the actively 
dividing glial cells to use the products of cell division. However, it had a 
major drawback. Viral toxicity could not be controlled because of loss 
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Fig. 1: Illustration of mechanism of action of oncolytic viruses
Table 1: Viruses which are effective against various malignancies in vitro studies
Viral strain Malignancy
Adenovirus AdV5 strain Glioma
Reovirus Against various tumors in nude mice model
New castle virus Against pediatric sarcomas
Parvovirus Adult glioma
Measles virus Glioma, medulloblastoma
Sabin polio (PVS-RIPO) strain Adult glioma
Vesicular stomatitis virus Grade IV astrocytoma
Seneca valley virus Pediatric malignancies
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Polio virus PVSRIPO Intratumoral I Trial expected to complete by 2017
of sensitivity to Ganciclovir whose site of action is the viral thymidine 
kinase. This prevented further advancement to clinical trials but paved 
way for better strains [6]. Another herpes strain G207 is showing 
premising results without infectivity [7].
Table 2: List of oncolytic virotherapy clinical trials under evaluation
98
Asian J Pharm Clin Res, Vol 10, Issue 10, 2017, 96-98
 Chary and Bharatwaj 
So far, virotherapy studies for meningiomas have been attempted at 
human-derived models and cultures. One significant study involved 
patient-derived cultures that were grafted into immunodeficient 
mice, leading to development of subdural tumors. To this, G47 delta 
herpes strain was subjected. This extended the survival of the mice 
with the tumor [8]. Another study involved cultures obtained from 
12 glioblastoma patients, following which replication competent 
adenoviruses were allowed to infect these cultures. Efficient results 
were obtained and clinical trials are now underway [9].
Apart from viruses mentioned above and central nervous tumors, many 
other viral strains are being employed for much different indication. 
Advances in genetic engineering attenuate the viral infectivity while 
retaining tumor remission property. The list of other oncolytic viral 
therapy is enlisted in Table 1.
Many clinical trials and metal analysis finding are in need to provide 
the evidence-based results of oncolytic viral therapy [10]. Cancer 
prevalence is on inclining trend in both developed and developing 
nation, and still, there is an unmet need to reduce its morbidity and 
mortality. Oncolytic virotherapy is expected to cause paradigm shift in 
cancer therapeutics [11-14].
CONCLUSION
Oncolytic viral therapy can be as effective as targeted therapy in 
battling against cancer; however, long-term efficacy and safety should 
be established from more studies and meta-analysis.
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